Cargando…

Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease

BACKGROUND: Phosphorylated tau (p-tau) epitopes in cerebrospinal fluid (CSF) are accurate biomarkers for a pathological and clinical diagnosis of Alzheimer's disease (AD) and are seen to be increased in preclinical stage of the disease. However, it is unknown if these increases transpire earlie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ashton, Nicholas J., Benedet, Andréa L., Pascoal, Tharick A., Karikari, Thomas K., Lantero-Rodriguez, Juan, Brum, Wagner S., Mathotaarachchi, Sulantha, Therriault, Joseph, Savard, Melissa, Chamoun, Mira, Stoops, Erik, Francois, Cindy, Vanmechelen, Eugeen, Gauthier, Serge, Zimmer, Eduardo R., Zetterberg, Henrik, Blennow, Kaj, Rosa-Neto, Pedro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850760/ https://www.ncbi.nlm.nih.gov/pubmed/35158308 http://dx.doi.org/10.1016/j.ebiom.2022.103836

Ejemplares similares

Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology
por: Ashton, Nicholas J., et al.
Publicado: (2021)

Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals
por: Benedet, Andréa L., et al.
Publicado: (2019)

Association of plasma P-tau181 with memory decline in non-demented adults
por: Therriault, Joseph, et al.
Publicado: (2021)

Comparing tau status determined via plasma pTau181, pTau231 and [(18)F]MK6240 tau-PET
por: Tissot, Cécile, et al.
Publicado: (2022)

Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals
por: Lussier, Firoza Z, et al.
Publicado: (2021)

Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer’s disease
por: Tissot, Cécile, et al.
Publicado: (2021)

Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer's disease
por: Tissot, Cécile, et al.
Publicado: (2021)

Amyloid‐dependent and amyloid‐independent effects of Tau in individuals without dementia
por: Therriault, Joseph, et al.
Publicado: (2021)

Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer’s disease
por: Kang, Min Su, et al.
Publicado: (2020)

Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairment
por: Pascoal, Tharick A., et al.
Publicado: (2020)

Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer’s disease continuum
por: Gobom, Johan, et al.
Publicado: (2022)

Impact of long- and short-range fibre depletion on the cognitive deficits of fronto-temporal dementia
por: Savard, Melissa, et al.
Publicado: (2022)

APOEε4 potentiates the relationship between amyloid-β and tau pathologies
por: Therriault, Joseph, et al.
Publicado: (2020)

A three‐range approach enhances the prognostic utility of CSF biomarkers in Alzheimer's disease
por: Brum, Wagner S., et al.
Publicado: (2022)

Biomarker modeling of Alzheimer’s disease using PET-based Braak staging
por: Therriault, Joseph, et al.
Publicado: (2022)

CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals
por: Simrén, Joel, et al.
Publicado: (2022)

Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts
por: Lantero-Rodriguez, Juan, et al.
Publicado: (2023)

The accuracy and robustness of plasma biomarker models for amyloid PET positivity
por: Benedet, Andréa L., et al.
Publicado: (2022)

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
por: Milà-Alomà, Marta, et al.
Publicado: (2022)

In vivo quantification of neurofibrillary tangles with [(18)F]MK-6240
por: Pascoal, Tharick A., et al.
Publicado: (2018)

Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
por: Milà-Alomà, Marta, et al.
Publicado: (2022)

Differences between blood and cerebrospinal fluid glial fibrillary Acidic protein levels: The effect of sample stability
por: Simrén, Joel, et al.
Publicado: (2022)

Diagnostic accuracy of the plasma ALZpath pTau217 immunoassay to identify Alzheimer’s disease pathology
por: Ashton, Nicholas J., et al.
Publicado: (2023)

Interactive rather than independent effect of APOE and sex potentiates tau deposition in women
por: Wang, Yi-Ting T, et al.
Publicado: (2021)

Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected
por: Suárez‐Calvet, Marc, et al.
Publicado: (2020)

Anosognosia predicts default mode network hypometabolism and clinical progression to dementia
por: Therriault, Joseph, et al.
Publicado: (2018)

Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [(18)F]THK5351 uptake in progressive supranuclear palsy
por: Ng, Kok Pin, et al.
Publicado: (2019)

Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer’s disease
por: Ng, Kok Pin, et al.
Publicado: (2021)

Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231
por: Bayoumy, Sherif, et al.
Publicado: (2021)

Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease
por: Kac, Przemysław R., et al.
Publicado: (2022)

Aβ-induced vulnerability propagates via the brain’s default mode network
por: Pascoal, Tharick A., et al.
Publicado: (2019)

Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer’s disease
por: Nilsson, Johanna, et al.
Publicado: (2022)

Mild behavioral impairment is associated with β‐amyloid but not tau or neurodegeneration in cognitively intact elderly individuals
por: Lussier, Firoza Z., et al.
Publicado: (2020)

Characterizing biomarker features of cognitively normal individuals with ventriculomegaly
por: Li, Xiaofeng, et al.
Publicado: (2017)

The prevalence and biomarkers’ characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database
por: Ba, Maowen, et al.
Publicado: (2017)

VoxelStats: A MATLAB Package for Multi-Modal Voxel-Wise Brain Image Analysis
por: Mathotaarachchi, Sulantha, et al.
Publicado: (2016)

Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring
por: Ashton, Nicholas J., et al.
Publicado: (2022)

Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke
por: De Vos, Ann, et al.
Publicado: (2017)

Tau in cerebrospinal fluid induces neuronal hyperexcitability and alters hippocampal theta oscillations
por: Brown, Jessica, et al.
Publicado: (2023)

Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer’s disease
por: Pascoal, Tharick A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8kh4gtk40c6o80u278n3k8bm7r